CD19 and B-cell chronic lymphocytic leukemia: Figure 3B demonstrates that the α-hTERT mAb binds CLL cells gated as CD5+/CD19+. Figure 3C,D depict that the α-hTERT mAb binds ex vivo to CD19+/CD5+ cells from the newly diagnosed patient and similarly diagnosed patient after treatment against CLL, respectively. Figure 4 shows that the percentage of the α-hTERT mAb positive cells detected by the flow cytometry in Tel-Aviv university laboratory is very similar to the percentage of CLL (CD19+/CD5+) cells identified by the flow cytometry unit at the Beilinson hospital.